Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Liminal BioSciences Inc. LMNL

Healthcare Biotechnology

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed... see more

Add To Watchlist

Recent & Breaking News (NDAQ:LMNL)

Prometic's Plasminogen (Ryplazim™) granted orphan drug designation for the treatment of idiopathic pulmonary fibrosis (IPF)

Canada NewsWire December 18, 2017

Prometic's PBI-4050 Receives Promising Innovative Medicine (PIM) Designation From The UK MHRA In The Treatment Of Idiopathic Pulmonary Fibrosis

Canada NewsWire December 11, 2017

Pivotal Data for Prometic's Intravenous Plasminogen Replacement Therapy to Be Presented at American Society for Hematology

PR Newswire December 6, 2017

Prometic announces the closing of its USD $80 million (CAD $100 million) line of credit with Structured Alpha LP, an affiliate of Thomvest Asset Management Inc.

Canada NewsWire December 1, 2017

Prometic Reports Positive Interim Clinical Data from Ongoing Intravenous Immunoglobulin (IVIG) Pivotal Phase 3 Trial

Canada NewsWire November 22, 2017

ProMetic Life Sciences Inc. to Host Earnings Call

Accesswire November 14, 2017

Prometic Reports 2017 Third Quarter Highlights and Financial Results

Canada NewsWire November 13, 2017

Prometic to Report its Third Quarter 2017 Financial Results and to Hold Conference Call / Webcast

Canada NewsWire November 9, 2017

For the First Time Ever, There Will be a Full Week Dedicated to Plasminogen Deficiency (PLGD) !

PR Newswire November 2, 2017

Prometic receives clearance from the Swedish Medical Products Agency to initiate plasminogen clinical trial in chronic tympanic membrane perforation

Canada NewsWire November 1, 2017

Prometic receives clearance from the Swedish Medical Products Agency to initiate plasminogen diabetic foot ulcer Phase 2 clinical trial

PR Newswire October 26, 2017

Prometic Receives Fast Track Designation for PBI-4050 in Development for Idiopathic Pulmonary Fibrosis (IPF)

PR Newswire October 25, 2017

Prometic enters into binding letter of intent to secure USD $80 million (CAD $100 million) line of credit from Structured Alpha LP, an affiliate of Thomvest Asset Management Inc.

Canada NewsWire October 23, 2017

Prometic presents PBI-4050 and PBI-4547 in Vivo Data at American Association for the Study of Liver Diseases (AASLD) Meeting

Canada NewsWire October 20, 2017

Prometic Receives Priority Review Status From Health Canada for Plasminogen (Ryplazim™)

PR Newswire October 19, 2017

Prometic Announces FDA Acceptance of its Biologics License Application for Plasminogen (Ryplazim™)

PR Newswire October 13, 2017

Prometic receives FDA clearance of its IND to initiate pivotal PBI-4050 Phase 2/3 trial in patients with idiopathic pulmonary fibrosis

Canada NewsWire September 25, 2017

Prometic Reports Positive Clinical Data from Ongoing PBI-4050 Study in Alström Syndrome Patients

Canada NewsWire September 19, 2017

/R E P E A T -- Prometic to Present at Two U.S. Investor Conferences in September/

Canada NewsWire September 11, 2017

Prometic to Present at Two U.S. Investor Conferences in September

Canada NewsWire September 8, 2017